FDA Requests Labeling Details For Roche’s Actemra In “Complete Response” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
“Complete Response” letter leads Roche to look past initial goal date for approval.
You may also be interested in...
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Roche expects to submit a complete response to FDA for the first-in-class IL-6 inhibitor for rheumatoid arthritis in the third quarter next year.
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Roche expects to submit a complete response to FDA for the first-in-class IL-6 inhibitor for rheumatoid arthritis in the third quarter next year.
Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance
Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.